Company new: Suven Life Sciences

| Updated on November 13, 2018 Published on November 13, 2018

Suven Life Sciences on Tuesday said it had been granted a product patent from Australia and another from Hong Kong. The patents correspond to the New Chemical Entities for the treatment of disorders associated with neurodegenerative diseases and are valid through 2036 and 2033, respectively. The granted claims are for the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer's disease, Attention Deficient Hyperactivity Disorder, Huntington’s disease, Parkinson’s and schizophrenia. Shares of Suven Life edged down 0.49 per cent at ₹252.60 on the BSE.

Published on November 13, 2018
This article is closed for comments.
Please Email the Editor